Navigation Links
Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Date:5/9/2011

ry.htm">electroporation device in a randomized, placebo-controlled, double-blind Phase II clinical study. We believe that these newly reported Phase I data showing long term persistence of antigen-specific T cells further support our confidence and  optimism for ultimately meeting the primary endpoint of this Phase II efficacy study: the clearance of CIN 2/3 lesions, measured at month 9, after three vaccinations at months 0, 1, and 3," concluded Dr. Kim.  

This recently initiated Phase II study will enroll 148 patients with CIN 2/3 or CIN 3 at approximately 25 study centers in the US, Korea, South Africa, Australia, and Canada. The study will also assess humoral and cell mediated immune responses to VGX-3100 in blood samples taken prior to the first vaccine dose and periodically thereafter. Cervical samples will be analyzed for evidence of immune responses in the cervix at baseline and subsequent intervals. Subjects will also be monitored for tolerability and safety.

The clinical trial protocol, HPV-003, is available at: http://clinicaltrials.gov/ct2/show/NCT01304524?term=NCT01304524&rank=1.

About Cervical Dysplasias/Cancers

Human papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer. At any given time, approximately 10% of women worldwide are infected with HPV. While roughly 70% of HPV infections are cleared by the body on its own, persistent HPV can lead to dysplasia, or premalignant changes in cells, of the cervix. Researchers have estimated the global prevalence of clinically pre-cancerous HPV infections at between 28 and 40 million. Persistent dysplasias may then progress to cancer. Every year, 510,000 cases of cervical cancer are diagnosed worldwide, and about 288,000 of the afflicted women, primarily in developing countries, die.

Preventive vaccines such as GARDASIL® and
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
4. Vanda Pharmaceuticals Reports First Quarter 2011 Results
5. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
6. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
10. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
11. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla ... Forecast (2011 - 2016)," analyzes the chocolate market ... major market drivers, restraints, and opportunities for the chocolate ... global chocolate market is expected to grow from $83.2 ... estimated CAGR of 2.7% from 2011 to 2016. , ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... Human Genome Sciences, Inc. (Nasdaq: HGSI ... Annual JPMorgan Healthcare Conference will be webcast and may ... )A member of Human Genome Sciences, senior management ... Wednesday, January 14, 2009 at 7:30 am Pacific Time ...
... Human Bionics Inc., "Victhom" (TSX: VHB), today announced ... www.victhom.com . The Website features a new ... operating divisions; Neurobionix, which is developing an implantable ... is developing and manufacturing computerized prostheses for above-knee ...
... SANTA CLARA, Calif., Jan. 9 GlaxoSmithKline and XenoPort, ... Drug Application (NDA) to the U.S. Food and Drug ... enacarbil) Extended Release Tablets for the treatment ... FDA had requested that the data in a single ...
Cached Biology Technology:Victhom Announces Launch of Enhanced Company Website 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... - Strategies for pursuing an HIV cure, the impact ... innovative models for HIV testing and care feature heavily ... cures" and the benefits of early antiretroviral therapeutic treatment ... 20I3 conference, the worlds leading open HIV scientific forum, ...
... down cell walls faster leading to less ... systems are brought together in an industrial setting, ... Energy Laboratory suggests. A paper on the ... Synergistic Mechanisms in Cellulose Deconstruction," appears in the ...
... sensor deployed by Woods Hole Oceanographic Institution (WHOI) in Gulf ... or harmful algal blooms (HABs) are monitored and managed in ... last month, and a second such system will be deployed ... to weekly real-time forecasts of New England red tide this ...
Cached Biology News:IAS 2013 conference program live online 2IAS 2013 conference program live online 3Combining strategies speeds the work of enzymes 2New robotic instruments to provide real-time data on Gulf of Maine red tide 2New robotic instruments to provide real-time data on Gulf of Maine red tide 3New robotic instruments to provide real-time data on Gulf of Maine red tide 4
... Performance The TSQ Quantum Ultra defines ... bioanalytical and environmental analysis. It features ... APCI probes, a titanium skimmer with superior ... and sensitivity. Its redesigned ion transfer ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... a tetramethylrhodamine-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
... and Bruker BioSpins Metabolic Profiler is ... and analysis of complex mixtures. It ... optional Avance NMR spectrometer and integrated ... statistical analysis for applications like:,Assessment of ...
Biology Products: